Karadža-Lapić Ljerka, Pikivaca Tamara, Pervan Petra, Jović Zlatović Josipa, Delin Sanja, Prkačin Ingrid
Department of Otorhinolaryngology, General Hospital Šibenik, Šibenik, Croatia.
University of Zagreb, School of Medicine Zagreb, Zagreb, Croatia; Public Health Centre Zagreb, Zagreb, Croatia.
Acta Med Acad. 2018 May;47(1):11-17. doi: 10.5644/ama2006-124.210.
Angioedema (AE) is a potentially life-threatening event. We investigated the etiology of AE, with the emphasis on bradykinininduced angioedema treatment in emergency medicine.
The retrospective study included 237 patients with AE, who were examined and treated in two hospitals (group A and B) in Croatia from 2009 to 2016. The location and duration of AE, data about chronic diseases and treatment, potential causative agents (food, drugs, insect bites and chemicals), physical examination data and the subsequent treatment were analyzed.
There was no statistical difference regarding age or comorbidities but there was a statistically significant difference in etiology between the groups (Chi-square, P=0.03). Renin-angiotensin-aldosterone system (RAAS) blocker induced AE was the main cause of emergency attendance in group A (37.5%) and among the leading causes in group B (18.8%). Bradykinin-induced AE (hereditary angioedema (HAE) and RAAS-AE) were the leading causes in a total of 75 (31.5%) patients. RAAS-AE was treated with glucocorticoids and antihistamines. HAE attacks in both groups (2/7 patients, 1.5/6%) were treated with specific therapy. Other causes of AE in groups A/B were insect bites (15/23 patients, 13.5/20%), use of antibiotics/analgetics (11/17 patients, 9/15%), gastroesophageal reflux disease (10/11 patients, 8/9%), neoplasms (5/6 patients, 4/5%) and idiopatic (32/31 patients, 26.5/26%). 21% of patients were hospitalized.
Bradykinin-mediated AE was the main cause of emergency attendance associated with AE. Advances in the treatment of HAE, with case reports of patients with RAAS-AE treated with C1 esterase inhibitor concentrate or bradykinin receptor antagonist, may prove to be a new, reliable and efficacious therapy option.
血管性水肿(AE)是一种可能危及生命的事件。我们对AE的病因进行了调查,重点是急诊医学中缓激肽诱导的血管性水肿的治疗。
这项回顾性研究纳入了237例AE患者,他们于2009年至2016年在克罗地亚的两家医院(A组和B组)接受检查和治疗。分析了AE的部位和持续时间、慢性病及治疗数据、潜在病因(食物、药物、昆虫叮咬和化学物质)、体格检查数据及后续治疗情况。
两组患者在年龄或合并症方面无统计学差异,但病因存在统计学显著差异(卡方检验,P = 0.03)。肾素 - 血管紧张素 - 醛固酮系统(RAAS)阻滞剂诱导的AE是A组急诊就诊的主要原因(37.5%),也是B组的主要病因之一(18.8%)。缓激肽诱导的AE(遗传性血管性水肿(HAE)和RAAS - AE)是总共75例(31.5%)患者的主要病因。RAAS - AE采用糖皮质激素和抗组胺药治疗。两组中的HAE发作(2/7例患者,1.5/6%)均采用特异性疗法治疗。A/B组中AE的其他病因包括昆虫叮咬(15/23例患者,13.5/20%)、使用抗生素/镇痛药(11/17例患者,9/15%)、胃食管反流病(10/11例患者,8/9%)、肿瘤(5/6例患者,4/5%)和特发性(32/31例患者,26.5/26%)。21%的患者住院治疗。
缓激肽介导的AE是与AE相关的急诊就诊的主要原因。HAE治疗方面的进展,以及使用C1酯酶抑制剂浓缩物或缓激肽受体拮抗剂治疗RAAS - AE患者的病例报告,可能证明是一种新的、可靠且有效的治疗选择。